Tuberculous Pericarditis in a Patient with COVID-19

J Appl Lab Med. 2023 May 4;8(3):645-648. doi: 10.1093/jalm/jfac139.

Authors

Smriti Srivastava¹, Neha Sharad¹, Aparna Ningombam², Devesh Kumar³, Rajesh Malhotra⁴, Purva Mathur²

Affiliations

¹ Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
² Department of Laboratory Medicine, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.
³ Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
⁴ Department of Orthopaedic, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India.

PMID: 36759918
DOI: 10.1093/jalm/jfac139

No abstract available

MeSH terms

Antitubercular Agents / therapeutic use
COVID-19* / complications
Humans
Pericarditis, Tuberculous* / complications
Pericarditis, Tuberculous* / diagnosis
Pericarditis, Tuberculous* / drug therapy

Substances

Antitubercular Agents